Subscribe to:
POZ magazine E-newsletters
POZ Personals Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents


Grin and Cast It

City of Love

Down and Out in L.A.

As Cool as Ice

The Secret Life of Syphilis

Easy Rider

Wheel of Misfortune

Raising Lazio

Neg & Pos

Love Connection

Pick Me!

Comic Belief

Daytime Drama

Catching Up With

La Quinceañera de Allgo

Survivor: The Sex Episode

Milestones

A Watched Pot Boils

Herb Of The Month

Staying Syphi-less

Shelf Life

Pure Gene-ius

Chug-A-Bug

Time for T

Delayed Reaction

Comfort Zone

The Alopecia Trail

Commanding Heights

Patriot's Day

Micro Money

11.3.89 Film Noir

Athletic Supporters

S.O.S

Mailbox


Most Talked About

Does Undetectable Equal Uninfectious? (21)

Just Found Out? A POZ.com Guide for HIV Rookies (11)

The Blood of Christ (a powerful one-man AIDS protest) (Blog) (9)

The State of AIDS in Puerto Rico (9)

Rethinking Criminalization of HIV (8)

Life Expectancy With HIV Increases Dramatically (6)

Most Popular Lessons

The HIV Life Cycle

Herpes Simplex Virus

Human Papilloma Virus (HPV)

Shingles

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)



emailrssprint

November 2000


Delayed Reaction

by Lark Lands

The longstanding rule for Glaxo Wellcome's abacavir (Ziagen) has been that those who experience hypersensitivity (allergic reactions) during their initial use of the drug (3 to 5 percent of users) must stop it and never restart it, because the second go-round could result in extreme reactions, even death. Now the company has sent a letter to warn physicians -- and added info to its "black box" package-insert warning -- that any reintroduction of the drug, even for those who think they never had a reaction, must be done very carefully. The heightened vigilance comes after reports of unexpectedly severe reactions -- most within hours, but some days or weeks later -- in those restarting the drug after discontinuation due to health problems thought to be unrelated to the med.

The problem is that some of the nonspecific symptoms of abacavir hypersensitivity may have been missed or misdiagnosed as respiratory or gastrointestinal (GI) tract infections, allergies to other meds, or other problems common among HIVers. Among first-timers who have reactions, complaints include: fever (seen in 80 percent); rash (60 to 70 percent); headache (60 percent), generally feeling bad or low in energy (60 percent); GI problems including nausea, vomiting, diarrhea or stomach pain (50 percent); and cough, shortness of breath or sore throat (20 percent). Other less common symptoms include itching, swelling, joint and body aches. Most reactions among abacavir first-timers occur during the first six weeks on the drug, but in some cases develop months later, so even longtime users can't be certain they're home free.

So for those thinking about reintroducing the drug after more than a missed dose or two, any prior symptoms even remotely suggesting a previous reaction mean an automatic thumbs-down. And suspicious past or not, going back to abacavir should be done always with caution and only under a doc's supervision, with quick access to emergency care. If, after restarting the drug, any symptoms develop, don't just stiff-upper-lip it -- get on the horn to your doc right away.

emailrssprint

[Go to top]
Get Started
Get Answers
What to do if you've just been diagnosed
How to find a support system
Things you should know before starting treatment
How to handle side effects and other concerns
How to tell someone you have HIV/AIDS

Talk to Us
Weekly Poll
Question: Do you agree with Former President Bill Clinton's comments that Barack Obama is ready to fight the AIDS epidemic in the United States?
Yes
No
Not sure

Monthly Poll
Question: Is the Latino community excluded  from conversations about the domestic AIDS crisis?
Yes
No

Surveys
Tell us about your pets.

Do you use social-networking sites?

more surveys  
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertise/contact us | site map]
© 2008 Smart + Strong. All Rights Reserved. Terms of use and Your privacy